Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04836832
Title Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Narendranath Epperla

follicular lymphoma

marginal zone B-cell lymphoma


Acalabrutinib + Duvelisib

Age Groups: adult | senior
Covered Countries

No variant requirements are available.